Stay updated on iRECIST DCR Evaluation in MMR/MSI CRC on Nivolumab+Ipilimumab Clinical Trial
Sign up to get notified when there's something new on the iRECIST DCR Evaluation in MMR/MSI CRC on Nivolumab+Ipilimumab Clinical Trial page.

Latest updates to the iRECIST DCR Evaluation in MMR/MSI CRC on Nivolumab+Ipilimumab Clinical Trial page
- ChecktodayNo Change Detected
- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedThe page revision label at the bottom changes from v3.5.2 to v3.5.3, indicating a minor site release update without altering the study details.SummaryDifference0.1%

- Check22 days agoChange DetectedRevision history updated to include v3.5.2 and remove v3.5.0.SummaryDifference0.1%

- Check51 days agoChange DetectedUpdated the page’s revision tag from v3.4.3 to v3.5.0.SummaryDifference0.1%

- Check66 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3.SummaryDifference0.1%

- Check87 days agoChange DetectedRevision updated from v3.4.1 to v3.4.2. No user-facing content or study information appears to be affected. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check95 days agoChange DetectedPage revision updated from v3.4.0 to v3.4.1; no substantive study details, outcomes, or eligibility information appear to be affected. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to iRECIST DCR Evaluation in MMR/MSI CRC on Nivolumab+Ipilimumab Clinical Trial
Enter your email address, and we'll notify you when there's something new on the iRECIST DCR Evaluation in MMR/MSI CRC on Nivolumab+Ipilimumab Clinical Trial page.